Allergan plc (NYSE:AGN) Shares Sold by Parisi Gray Wealth Management

Parisi Gray Wealth Management decreased its holdings in Allergan plc (NYSE:AGN) by 23.7% in the 1st quarter, HoldingsChannel reports. The fund owned 463 shares of the company’s stock after selling 144 shares during the quarter. Parisi Gray Wealth Management’s holdings in Allergan were worth $68,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Allergan by 2.9% in the fourth quarter. BlackRock Inc. now owns 21,466,017 shares of the company’s stock valued at $2,869,149,000 after purchasing an additional 600,535 shares during the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of Allergan by 14,208.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 20,762,744 shares of the company’s stock worth $155,000 after purchasing an additional 20,617,639 shares during the period. Artisan Partners Limited Partnership raised its holdings in shares of Allergan by 6.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 6,767,753 shares of the company’s stock worth $990,867,000 after purchasing an additional 410,746 shares during the period. Longview Partners Guernsey LTD raised its holdings in shares of Allergan by 288.6% in the 4th quarter. Longview Partners Guernsey LTD now owns 6,026,108 shares of the company’s stock worth $805,450,000 after purchasing an additional 4,475,447 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Allergan by 27.6% during the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after buying an additional 1,265,742 shares during the period. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Several equities research analysts recently commented on AGN shares. Wells Fargo & Co reiterated a “buy” rating and set a $189.00 target price (down from $202.00) on shares of Allergan in a report on Thursday, March 7th. JPMorgan Chase & Co. restated an “overweight” rating and set a $200.00 price objective on shares of Allergan in a research note on Thursday, March 7th. They noted that the move was a valuation call. Stifel Nicolaus restated a “hold” rating and set a $175.00 price objective on shares of Allergan in a research note on Thursday, March 7th. Credit Suisse Group lowered their price objective on Allergan from $161.00 to $155.00 and set a “neutral” rating for the company in a research note on Thursday, March 7th. Finally, ValuEngine upgraded Allergan from a “strong sell” rating to a “sell” rating in a research note on Thursday, March 7th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $175.30.

Shares of AGN traded down $3.04 during mid-day trading on Friday, hitting $117.96. The stock had a trading volume of 55,447 shares, compared to its average volume of 2,686,952. The firm has a market cap of $39.21 billion, a price-to-earnings ratio of 7.08, a PEG ratio of 1.12 and a beta of 1.39. The company has a current ratio of 0.71, a quick ratio of 0.60 and a debt-to-equity ratio of 0.32. Allergan plc has a fifty-two week low of $120.68 and a fifty-two week high of $197.00.

Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.55 by $0.24. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The business had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.55 billion. During the same quarter in the previous year, the firm posted $3.74 EPS. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. On average, sell-side analysts predict that Allergan plc will post 16.68 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Tuesday, May 14th will be given a dividend of $0.74 per share. The ex-dividend date of this dividend is Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a yield of 2.51%. Allergan’s dividend payout ratio is currently 17.74%.

ILLEGAL ACTIVITY NOTICE: “Allergan plc (NYSE:AGN) Shares Sold by Parisi Gray Wealth Management” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2019/06/14/allergan-plc-nyseagn-shares-sold-by-parisi-gray-wealth-management.html.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Read More: How do buyers and sellers choose a strike price?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.